Human CD4+CD25+ regulatory T cells are sensitive to low dose cyclophosphamide: Implications for the immune response

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Heylmann, Daniel ^a   Bauer, Martina ^a   Becker, Huong ^a   Van Gool, Stefaan ^b   Bacher, Nicole ^a   Steinbrink, Kerstin ^a   Kaina, Bernd ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ALPHA; MAFOSFAMIDE;

ANALOGS AND DERIVATIVES; APOPTOSIS; CHEMICALLY INDUCED; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; HUMAN; IMMUNOLOGY; METABOLISM; NECROSIS; REGULATORY T LYMPHOCYTE;

APOPTOSIS; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; NECROSIS; T-LYMPHOCYTES, REGULATORY;

EID: 84893499231     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083384     Document Type: Article

References (28)

1. Sakaguchi S (2000) Regulatory T cells: key controllers of immunologic self-tolerance. Cell 101: 455-458.
2. Beissert S, Schwarz A, Schwarz T (2006) Regulatory T cells. J Invest Dermatol 126: 15-24. (Pubitemid 43336089)
3. Vignali DA, Collison LW, Workman CJ (2008) How regulatory T cells work. Nat Rev Immunol 8: 523-532.
4. Wang HY, Lee DA, Peng G, Guo Z, Li Y, et al. (2004) Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity 20: 107-118. (Pubitemid 38134298)
5. Wainwright DA, Sengupta S, Han Y, Lesniak MS (2011) Thymus-derived rather than tumor-induced regulatory T cells predominate in brain tumors. Neuro Oncol 13: 1308-1323.
6. Emadi A, Jones RJ, Brodsky RA (2009) Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol 6: 638-647.
7. Sharabi A, Haran-Ghera N (2011) Immune recovery after cyclophosphamide treatment in multiple myeloma: implication for maintenance immunotherapy. Bone Marrow Res 2011: 269519.
8. Joy MS, La M, Wang J, Bridges AS, Hu Y, et al. (2012) Cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitis. Br J Clin Pharmacol 74: 445-455.
9. Goldstein M, Roos WP, Kaina B (2008) Apoptotic death induced by the cyclophosphamide analogue mafosfamide in human lymphoblastoid cells: contribution of DNA replication, transcription inhibition and Chk/p53 signaling. Toxicol Appl Pharmacol 229: 20-32.
10. Matthias M, Sohr R, Preiss R, Brockmann B (1984) [Bioavailability of cyclophosphamide following oral administration in high doses]. Onkologie 7: 48-49.
11. Ercolini AM, Ladle BH, Manning EA, Pfannenstiel LW, Armstrong TD, et al. (2005) Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med 201: 1591-1602. (Pubitemid 40723662)
12. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, et al. (2005) Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105: 2862-2868. (Pubitemid 40446280)
13. Sharabi A, Laronne-Bar-On A, Meshorer A, Haran-Ghera N (2010) Chemoimmunotherapy reduces the progression of multiple myeloma in a mouse model. Cancer Prev Res (Phila) 3: 1265-1276.
14. Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, et al. (2004) CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 34: 336-344. (Pubitemid 39255944)
15. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, et al. (2012) Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med.
16. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, et al. (2007) Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 56: 641-648. (Pubitemid 46348738)
17. Ge Y, Domschke C, Stoiber N, Schott S, Heil J, et al. (2012) Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. Cancer Immunol Immunother 61: 353-362.
18. Zhao J, Cao Y, Lei Z, Yang Z, Zhang B, et al. (2010) Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels. Cancer Res 70: 4850-4858.
19. Usanova S, Piee-Staffa A, Sied U, Thomale J, Schneider A, et al. (2010) Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression. Mol Cancer 9: 248.
20. Lefrere F, Makke J, Fermand J, Marolleau J, Dal Cortivo L, et al. (1999) Blood stem cell collection using chemotherapy with or without systematic G-CSF: experience in 52 patients with multiple myeloma. Bone Marrow Transplant 24: 463-466. (Pubitemid 29423623)
21. Tomasz M, Palom Y (1997) The mitomycin bioreductive antitumor agents: cross-linking and alkylation of DNA as the molecular basis of their activity. Pharmacol Ther 76: 73-87. (Pubitemid 28078561)
22. Cai J, Bhatnagar A, Pierce WM Jr (2009) Protein modification by acrolein: formation and stability of cysteine adducts. Chem Res Toxicol 22: 708-716.
23. Akimova T, Beier UH, Wang L, Levine MH, Hancock WW (2011) Helios expression is a marker of T cell activation and proliferation. PLoS One 6: e24226.
24. Khanna KK, Jackson SP (2001) DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 27: 247-254. (Pubitemid 32201842)
25. Roos WP, Kaina B (2013) DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis. Cancer Lett 332: 237-248.
26. Bauer M, Goldstein M, Christmann M, Becker H, Heylmann D, et al. (2011) Human monocytes are severely impaired in base and DNA double-strand break repair that renders them vulnerable to oxidative stress. Proc Natl Acad Sci U S A 108: 21105-21110.
27. Bauer M, Goldstein M, Heylmann D, Kaina B (2012) Human monocytes undergo excessive apoptosis following temozolomide activating the ATM/ATR pathway while dendritic cells and macrophages are resistant. PLoS One 7: e39956.
28. Liotta F, Gacci M, Frosali F, Querci V, Vittori G, et al. (2011) Frequency of regulatory T cells in peripheral blood and in tumour-infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma. BJU Int 107: 1500-1506.